LabGenomics Co. Ltd (084650) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LabGenomics Co. Ltd (084650) has a cash flow conversion efficiency ratio of -0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.41 Billion ≈ $-4.35 Million USD) by net assets (₩188.67 Billion ≈ $127.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of LabGenomics Co. Ltd for the company's overall valuation and market capitalisation.
LabGenomics Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LabGenomics Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LabGenomics Co. Ltd ranked by their cash flow conversion efficiency. Explore 084650 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mountain Province Diamonds Inc
TO:MPVD
|
2.361x |
|
Percheron Therapeutics Ltd
AU:PER
|
-0.716x |
|
Judges Scientific Plc
LSE:JDG
|
0.204x |
|
OCEAN-GEOLOOP AS NK -01
F:FQ4
|
N/A |
|
Audeara Ltd
AU:AUA
|
0.024x |
|
Dharani Sugars&Chemicals Limited
NSE:DHARSUGAR
|
-0.229x |
|
Masivo Silver Corp
V:MASS
|
-10.665x |
|
McChip Resources Inc
V:MCS
|
-0.076x |
Annual Cash Flow Conversion Efficiency for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of LabGenomics Co. Ltd from 2014 to 2024. View LabGenomics Co. Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩216.31 Billion ≈ $146.59 Million |
₩-12.99 Billion ≈ $-8.81 Million |
-0.060x | -665.89% |
| 2023-12-31 | ₩228.14 Billion ≈ $154.61 Million |
₩2.42 Billion ≈ $1.64 Million |
0.011x | -96.82% |
| 2022-12-31 | ₩209.33 Billion ≈ $141.86 Million |
₩69.87 Billion ≈ $47.35 Million |
0.334x | -19.46% |
| 2021-12-31 | ₩157.72 Billion ≈ $106.88 Million |
₩65.36 Billion ≈ $44.29 Million |
0.414x | -27.12% |
| 2020-12-31 | ₩81.54 Billion ≈ $55.26 Million |
₩46.37 Billion ≈ $31.43 Million |
0.569x | +442.57% |
| 2019-12-31 | ₩30.42 Billion ≈ $20.61 Million |
₩3.19 Billion ≈ $2.16 Million |
0.105x | +418.90% |
| 2018-12-31 | ₩30.10 Billion ≈ $20.40 Million |
₩608.03 Million ≈ $412.05K |
0.020x | +142.71% |
| 2017-12-31 | ₩22.35 Billion ≈ $15.14 Million |
₩-1.06 Billion ≈ $-716.24K |
-0.047x | -146.58% |
| 2016-12-31 | ₩25.04 Billion ≈ $16.97 Million |
₩2.54 Billion ≈ $1.72 Million |
0.102x | -5.37% |
| 2015-12-31 | ₩22.15 Billion ≈ $15.01 Million |
₩2.38 Billion ≈ $1.61 Million |
0.107x | -27.59% |
| 2014-12-31 | ₩21.24 Billion ≈ $14.39 Million |
₩3.15 Billion ≈ $2.13 Million |
0.148x | -- |
About LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.